Cell line expressing functional alpha1D-adrenergic receptors

Introduction The alpha1D-adrenergic receptor (AR) is a major regulator of cardiovascular and central nervous system function. Targeting AR is thus of major interest to the pharmaceutical industry for developing new medicines to treat hypertension and neurological disease. However, it has been impossible to screen for potential new
α1D–AR ligands because of the inability to obtain sufficient functional expression in cells. Technology description To overcome the lack of stable in vitro expression of AR, Dr Chris Hague’s lab has successfully developed cell lines that express functional α1D–AR and are suitable for high throughput screening for novel ligands that can be used for the treatment of diseases. The UW researchers found that dystrophins are forming a complex with AR both in vitro and in vivo, thereby ensuring proper functional expression of AR. The stable cell lines were generated through the transfection of HEK293 cells with
α1D–AR. Business opportunity Hypertension is a cardiovascular disease associated with overactivation of the sympathetic nervous system, and increased vascular tone. Finding novel AR ligands with pharmacological potential may lead to new treatment for hypertension, a market that is expected to reach $30 billion per year in worldwide revenues by 2010. Stage of development AR-expressing cell lines have been developed and characterized. Related Publications J. Biol. Chem. 2008 Jul 4;283(27):18792-800 For more information on this technology contact:
Valerie Carricaburu, Ph.D. Technology Manager, Invention Licensing carricav@u.washington.edu 206-543-3970

Type of Offer: Licensing



Next Patent »
« More Biotech Patents
« More Biomedical Patents

Share on      


CrowdSell Your Patent